The effect of EPO- and pHBSP-treatment on plasma metabolome in mice with Stx-induced experimental HUS

The metabolomic data provided here belong to a study that describes two different treatment strategies in a Shiga toxin (Stx)-induced model of hemolytic uremic syndrome (HUS) in mice. Despite intensive research, treatable targets in HUS are still missing and therapy is limited to intensive care. Here, two different potential therapeutics (erythropoietin–EPO and pyroglutamate helix B surface peptide–pHBSP) combined with volume resuscitation were tested in C57BL/6J wild type mice in a clinically relevant, recently published model of Stx-induced HUS. Animals were euthanized on day 7 of the experiment and blood, plasma and renal tissue samples were collected for analysis. Acute kidney injury was confirmed by kidney histology and laboratory parameters in plasma. Overall, metabolomic data from 32 C57BL/6J mouse plasma samples was analyzed. The mice were randomly assigned to one of the four treatment groups: sham, Stx+vehicle, Stx+EPO, Stx+pHBSP. A targeted metabolomics approach using an MxP® Quant 500 kit and mass spectrometry was performed at Biocrates Life Sciences.